Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy (Q38066127)

28 August 2017

1 reference

title

Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy (English)

1 reference

28 August 2017

main subject

anti-retroviral agent

0 references

1

Babafemi Taiwo

1 reference

28 August 2017

Luis Barcena

2

1 reference

28 August 2017

Randall Tressler

series ordinal

3

1 reference

28 August 2017

language of work or name

1 reference

1 March 2013

1 reference

28 August 2017

published in

Current HIV/AIDS reports

1 reference

28 August 2017

volume

10

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

21-32

1 reference

Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Premature age-related comorbidities among HIV-infected persons compared with the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Microbial translocation in HIV infection: causes, consequences and treatment opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Endotoxin-binding affinity of sevelamer: a potential novel anti-inflammatory mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

New scientific paradigms for probiotics and prebiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Effect of probiotic bacteria on microbial host defense, growth, and immune function in human immunodeficiency virus type-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Effect of treating co-infections on HIV-1 viral load: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Herpes simplex virus type 2 (HSV-2) as a coronary atherosclerosis risk factor in HIV-infected men: multicenter AIDS cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Role of CMV in immune senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Adaptive immunity in obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Anti-inflammatory effects of statins: clinical evidence and basic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Immunomodulation by statins: inhibition of cholesterol vs. isoprenoid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in HIV-infected patients treated with ritonavir-boosted protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Evaluation of the anti-HIV activity of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Statin-induced immunomodulatory effects on human T cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

The ability of chloroquine to prevent tat-induced cytokine secretion by monocytes is implicated in its in vivo anti-human immunodeficiency virus type 1 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Chloroquine mediated molecular tuning of astrocytes for enhanced permissiveness to HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Reduction of immune activation with chloroquine therapy during chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Tolerance and durability of abacavir/lamivudine (ABC/3TC)-containing regimens: results from a large prospective French cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Molecular action of methotrexate in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Inflammation, Immune Activation, and CVD Risk in Individuals With HIV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0147-3

Human Cytomegalovirus Induces Systemic Immune Activation Characterized by a Type 1 Cytokine Signature

21 January 2018

1 reference

12 December 2020

Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial

1 reference

12 December 2020

The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006

1 reference

12 December 2020

Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of

1 reference

12 December 2020

Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load

1 reference

12 December 2020

Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir

1 reference

12 December 2020

Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties.

1 reference

12 December 2020

Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States

1 reference

12 December 2020

Pharmacokinetic study of rifaximin after oral administration in healthy volunteers.

1 reference

12 December 2020

Statins as a newly recognized type of immunomodulator

1 reference

12 December 2020

Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals

1 reference

12 December 2020

Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses

1 reference

12 December 2020

Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis

1 reference

12 December 2020

Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection

1 reference

12 December 2020

10.1007/S11904-012-0147-3

Identifiers

DOI

1 reference

28 August 2017

1 reference